2型糖尿病患者胰腺VMAT2密度PET显像降低
采用[18F]氟丙基-二氢四苯嗪PET在16例健康肥胖者、5例糖尿病前期和17例2型糖尿病患者中定量胰腺VMAT2。胰腺各亚区SUVR-1与AIRargMAX正相关、与HbA1c及2型糖尿病病程负相关,提示β细胞质量丢失参与胰岛素分泌不足。
要点
- 胰腺VMAT2 PET显像在各胰腺亚区的绝对重测变异≤15%。
- SUVR-1与AIRargMAX在全胰腺及头、体、尾均呈正相关。
- SUVR-1与HbA1c及2型糖尿病病程在部分胰腺亚区呈负相关。
核心结论
- 胰腺及胰腺各亚区VMAT2密度与2型糖尿病病程、血糖控制和β细胞功能的相关性提示,β细胞质量丢失参与2型糖尿病患者的胰岛素分泌不足。
研究设计与样本
- 研究纳入16例健康肥胖志愿者、5例糖尿病前期和17例2型糖尿病患者,行动态PET采集4小时并测代谢物校正动脉血。
- 其中11例(6例健康肥胖志愿者和5例2型糖尿病患者)接受两次腹部PET/CT扫描以评估重测变异。
- 以脾为参考区计算胰腺头、体、尾的SUVR,取3-4小时数据,并以SUVR减1(SUVR-1)校正非特异性摄取。
- β细胞功能以精氨酸刺激试验(AST)后C肽释放及葡萄糖增强AST的急性胰岛素反应(AIRargMAX)评估。
主要发现
- 所有胰腺区域的绝对重测变异≤15%。
- SUVR-1与AIRargMAX在所有组中呈显著正相关:全胰腺p=0.009、胰头p=0.009、胰体p=0.019、胰尾p=0.023。
- SUVR-1与HbA1c在所有组中呈负相关:全胰腺p=0.033、胰头p=0.008。
- SUVR-1与2型糖尿病病程呈负相关:胰头p=0.049、胰尾p=0.035。
- 各组的SUVR-1均存在变异与重叠。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The progressive loss of beta cell function is part of the natural history of type 2 diabetes. Autopsy studies suggest that this is, in part, due to loss of beta cell mass (BCM), but this has not been confirmed in vivo. Non-invasive methods to quantify BCM may contribute to a better understanding of type 2 diabetes pathophysiology and the development of therapeutic strategies. In humans, the localisation of vesicular monoamine transporter type 2 (VMAT2) in beta cells and pancreatic polypeptide cells, with minimal expression in other exocrine or endocrine pancreatic cells, has led to its development as a measure of BCM. We used the VMAT2 tracer [18F]fluoropropyl-(+)-dihydrotetrabenazine to quantify BCM in humans with impaired glucose tolerance (prediabetes) or type 2 diabetes, and in healthy obese volunteers (HOV). METHODS: Dynamic positron emission tomography (PET) data were obtained for 4 h with metabolite-corrected arterial blood measurement in 16 HOV, five prediabetic and 17 type 2 diabetic participants. Eleven participants (six HOV and five with type 2 diabetes) underwent two abdominal PET/computed tomography (CT) scans for the assessment of test-retest variability. Standardised uptake value ratio (SUVR) was calculated in pancreatic subregions (head, body and tail), with the spleen as a reference region to determine non-specific tracer uptake at 3-4 h. The outcome measure SUVR minus 1 (SUVR-1) accounts for non-specific tracer uptake. Functional beta cell capacity was assessed by C-peptide release following standard (arginine stimulus test [AST]) and acute insulin response to the glucose-enhanced AST (AIRargMAX). Pearson correlation analysis was performed between the binding variables and the C-peptide AUC post-AST and post-AIRargMAX. RESULTS: Absolute test-retest variability (aTRV) was ≤15% for all regions. Variability and overlap of SUVR-1 was measured in all groups; HOV and participants with prediabetes and with type 2 diabetes. SUVR-1 showed significant positive correlations with AIRargMAX (all groups) in all pancreas subregions (whole pancreas p = 0.009 and pancreas head p = 0.009; body p = 0.019 and tail p = 0.023). SUVR-1 inversely correlated with HbA1c (all groups) in the whole pancreas (p = 0.033) and pancreas head (p = 0.008). SUVR-1 also inversely correlated with years since diagnosis of type 2 diabetes in the pancreas head (p = 0.049) and pancreas tail (p = 0.035). CONCLUSIONS/INTERPRETATION: The observed correlations of VMAT2 density in the pancreas and pancreas regions with years since diagnosis of type 2 diabetes, glycaemic control and beta cell function suggest that loss of BCM contributes to deficient insulin secretion in humans with type 2 diabetes.
引用
- Cline GW, Naganawa M, Chen L, et al. Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging. Diabetologia. 2018. PMID: 29721633. doi:10.1007/s00125-018-4624-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。